Background: Preclinical data suggest that metformin may reduce breast cancer incidence
and improve cancer prognosis. However, the current evidence in observational studies is …

Metformin is a widely used antidiabetic drug, and there is evidence among diabetic patients
that metformin is a chemopreventive agent against multiple cancers. There is also evidence …

Background. Diabetic patients with breast cancer receiving metformin and neoadjuvant
chemotherapy have a higher pathologic complete response rate than do diabetic patients …

Immunometabolism is an emerging discipline in cancer immunotherapy. Tumor tissues are
heterogeneous and influenced by metabolic reprogramming of the tumor immune …

Purpose Metformin may be associated with a decreased risk of breast cancer. We performed
a meta-analysis to assess the effect of metformin intake on breast cancer risk and mortality …

Background: Experiments have shown that metformin can inhibit cancer cell growth, but
clinical observations have been inconsistent, so we pooled the currently available data to …

Background Increased flux through both glycolytic and oxidative metabolic pathways is a
hallmark of breast cancer cells and is critical for their growth and survival. As such, targeting …

Increasing evidence suggests that metformin use is associated with a decreased risk of
cancer. The traditional therapies for gastric cancer (GC) are gastrectomy and …

Aims Equivocal results of association between metformin and cancer-specific survival need
more investigation. We tested the hypothesis that adherence to the drug had a lower cancer …

Abstract P-glycoprotein (P-gp) is one of the major obstacles to efficiency of cancer
chemotherapy. Here, we investigated whether combination of metformin and 2 …